Assay Formats: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team

As part of the GBC (Global Bioanalysis Consortium), the L3 assay format team has focused on reviewing common platforms used to support ligand binding assays in the detection of biotherapeutics. The following review is an overview of discussions and presentations from around the globe with a group of experts from different companies to allow an international harmonization of common practices and suggestions for different platforms. Some of the major platforms include Gyrolab, Erenna, RIA, AlphaLISA, Delfia, Immuno-PCR, Luminex, BIAcore, and ELISAs. The review is meant to support bioanalysts in taking decisions between different platforms depending on the needs of the analyte with a number of recommendations to help integration of platforms into a GLP environment.

[1]  Rosemary Lawrence-Henderson,et al.  Bioanalytical platform comparison using a generic human IgG PK assay format. , 2013, Journal of immunological methods.

[2]  Renuka Pillutla,et al.  Rapid development of multiple 'fit-for-purpose' assays on an automatic microfluidic system using a streamlined process in support of early biotherapeutics discovery programs. , 2013, Bioanalysis.

[3]  Lee Abberley,et al.  The Gyrolab™ immunoassay system: a platform for automated bioanalysis and rapid sample turnaround. , 2013, Bioanalysis.

[4]  Mark Ma,et al.  Automating bioanalytical sample analysis through enhanced system integration. , 2013, Bioanalysis.

[5]  Philip Timmerman,et al.  The European Bioanalysis Forum community's evaluation, interpretation and implementation of the European Medicines Agency guideline on Bioanalytical Method Validation. , 2013, Bioanalysis.

[6]  Xun Wang,et al.  Validation of a Gyrolab™ assay for quantification of rituximab in human serum. , 2012, Journal of pharmacological and toxicological methods.

[7]  Ronald R Bowsher,et al.  Development of a novel radioimmunoassay to detect autoantibodies to amyloid beta peptides in the presence of a cross-reactive therapeutic antibody. , 2011, Journal of pharmaceutical and biomedical analysis.

[8]  T. Tarasow,et al.  Microfluidic strategies applied to biomarker discovery and validation for multivariate diagnostics. , 2011, Bioanalysis.

[9]  Wei Song,et al.  Comparison of four distinct detection platforms using multiple ligand binding assay formats. , 2011, Journal of immunological methods.

[10]  Shibing Deng,et al.  Comparison of an antibody capture and a cell capture ligand-binding assay to quantify a monoclonal therapeutic in serum. , 2011, Bioanalysis.

[11]  Johanna R Mora,et al.  Biotherapeutic bioanalysis: a multi-indication case study review. , 2011, Bioanalysis.

[12]  Heather Myler,et al.  Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development , 2011, The AAPS Journal.

[13]  Johanna R Mora,et al.  Application of the Gyrolab™ platform to ligand-binding assays: a user's perspective. , 2010, Bioanalysis.

[14]  Michael Adler,et al.  Pharmacokinetics of natural mistletoe lectins after subcutaneous injection , 2010, European Journal of Clinical Pharmacology.

[15]  S. Agee,et al.  Analytical validation of a highly sensitive microparticle-based immunoassay for the quantitation of IL-13 in human serum using the Erenna immunoassay system. , 2009, Journal of immunological methods.

[16]  Anthony J. DeStefano,et al.  Workshop Report and Follow-Up—AAPS Workshop on Current Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples—Implications of Crystal City Recommendations , 2009, The AAPS Journal.

[17]  J. Todd,et al.  Ultrasensitive flow-based immunoassays using single-molecule counting. , 2007, Clinical chemistry.

[18]  Arunan Kaliyaperumal,et al.  Comparing ELISA and Surface Plasmon Resonance for Assessing Clinical Immunogenicity of Panitumumab , 2007, The Journal of Immunology.

[19]  Binodh DeSilva,et al.  Bioanalytical Method Validation for Macromolecules in Support of Pharmacokinetic Studies , 2005, Pharmaceutical Research.

[20]  L. Kux.  OF HEALTH AND HUMAN SERVICES Food and Drug Administration , 2014 .

[21]  R. Forster,et al.  Electrogenerated chemiluminescence. , 2009, Annual review of analytical chemistry.

[22]  C. T. Viswanathan,et al.  Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays , 2007, Pharmaceutical Research.

[23]  K. HayGlass,et al.  Comparison of chemiluminescent assays and colorimetric ELISAs for quantification of murine IL-12, human IL-4 and murine IL-4: chemiluminescent substrates provide markedly enhanced sensitivity. , 2001, Journal of immunological methods.